AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Hervycta 440 + Injection

Prescription Icon
Prescription Required

Marketer

Dr Reddy's Laboratories Ltd

Salt Composition

Trastuzumab (440mg)

Overview Hervycta 440 + Injection

Trastuzumab injection (440 mg) is indicated for treating breast and gastric cancers. Its mechanism involves targeting and eliminating cancerous cells by blocking HER2, a protein crucial for cancer cell growth. Administration is strictly via injection by a healthcare professional. Dosage and frequency are determined individually by your physician based on your condition and may be adjusted. Adhere precisely to the prescribed regimen; improper use or overdose may lead to severe complications. Therapeutic effects might not be immediately apparent, potentially requiring weeks or months; discontinue only under your doctor's direction. Common adverse effects include nausea, headache, skin rash, sleep disturbances, and infections. This medication can reduce blood cell counts, increasing infection risk. Regular blood tests monitoring blood cell levels, cardiac function, liver health, and uric acid are essential. Report immediately any shortness of breath, cough, chills, or limb swelling. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This treatment is contraindicated during pregnancy and breastfeeding. Reliable contraception is vital for both partners throughout the treatment period to prevent conception.

Uses of Hervycta 440 + Injection

Cancers affecting the breast and stomach

Major Benefits of Hervycta 440 + Injection:

This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.

Common Side effects of Hervycta 440 + Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Hervycta 440 + Injection:

This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.

How Hervycta 440 + Injection works:

Hervycta 440 + Injection, a recombinant IgG1 monoclonal antibody, targets HER2 (human epidermal growth factor receptor 2) receptors. Overexpression of these receptors drives uncontrolled growth in breast and gastric cancers. The injection neutralizes HER2, thereby eliminating cancer cells and disrupting several key oncogenic signaling cascades.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concomitant use of Hervycta 440 Injection and alcohol may result in significant somnolence.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Hervycta 440 + Injection during pregnancy poses a confirmed risk to the fetus. Therefore, it's contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known dangers. Always seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administration of Hervycta 440 Injection while breastfeeding is likely inadvisable. Preliminary human studies indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

The impact of Hervycta 440 + Injection on driving ability is undetermined. Refrain from operating a vehicle if you exhibit any symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

The use of Hervycta 440 + Injection in individuals with kidney impairment is likely safe. Preliminary evidence indicates dose modification may be unnecessary. Physician consultation is recommended.

LiverLiverCONSULT YOUR DOCTOR

Data regarding Hervycta 440 + Injection use in individuals with hepatic impairment is scarce. Physician consultation is advised.

What if you forget to take Hervycta 440 + Injection :

Omitting a scheduled Hervycta 440 + Injection necessitates contacting your physician.

Facts to Know About Hervycta 440 + Injection

LabelValue
Chemical Category Monoclonal antibody
Developing Habits No.
Treatment Category Cancer Medications
Action Category Monoclonal Antibody HER2/neu (ErbB2) Inhibitor

FAQs on Hervycta 440 + Injection

Hervycta 440 + Injection may cause side effects including sore throat, fever, chills, fatigue, pale skin, nosebleeds, and unusual bleeding or bruising. Other possible side effects are stomach pain, seizures, hallucinations, muscle cramps and spasms, nausea or vomiting, loss of appetite, rapid heartbeat, discolored or decreased urine output, painful urination, and signs of infection. Contact your doctor immediately if you experience any of these symptoms.
Women of childbearing age must use effective contraception throughout Hervycta 440 + Injection therapy and for seven months afterward. Pregnancy planning may resume seven months post-treatment.
Treatment with Hervycta 440 + Injection for early breast cancer patients should last one year, or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Hervycta 440 + Injection does not require fasting beforehand. Administration must be overseen by a physician experienced in administering cancer chemotherapy and performed only by a qualified healthcare professional.
Hervycta 440 + Injection is available in two formulations: intravenous infusion and subcutaneous injection. Always verify the correct formulation is administered as prescribed, checking the product label. The intravenous formulation must be given intravenously; it is not for subcutaneous use. Your doctor can switch your treatment between intravenous and subcutaneous formulations if clinically appropriate.
Hervycta 440 + Injection is a monoclonal antibody targeting the HER2 protein, found on the surface of some cancer cells. Because it works by binding to HER2 to inhibit cancer cell growth, it's only effective in patients with HER2-positive cancer and is not indicated for use in HER2-negative cancer.
Using Hervycta 440 + Injection with anthracycline-based cancer drugs (like doxorubicin) can harm your heart. Your doctor must assess your heart health before and during treatment.
Cardiac evaluations should begin at treatment initiation, continue every three months during treatment, and every six months post-treatment for up to 24 months following the final Hervycta 440 + Injection dose. Patients with pre-existing cardiac conditions require evaluation every twelve weeks.
Hervycta 440 + Injection
52,805
MRP 61,270
13% off